Post by
Hammertime5 on Jan 30, 2018 9:51am
LMT news - expands team - revenue in Q2/2018 California
RISE RESEARCH AND CONSTANCE THERAPEUTICS ANNOUNCE COMPREHENSIVE STRATEGIC PARTNERSHIP Toronto, Ontario January 30, 2018 RISE Research Inc. (RISE) and Luminor Medical Technologies Inc. (Luminor) (CSE: LMT) are pleased to announce RISEs comprehensive strategic partnership with Constance Therapeutics (CT), an established San Francisco-based developer and manufacturer of premium medical cannabis extract products for physician and patient use in California. The partnership includes a distribution agreement that will see RISE build and manage a retail sales and distribution channel for both CT and RISE products in the California market. RISE will deploy a direct sales team in the state to sign top-tier dispensaries, augmented by a personalized support program for customers and patients to be delivered at the store level. RISE expects to create a network of at least 240 premium store locations in California within the next 12 months. Leveraging its pharmaceutical grade product, know-how, and intellectual property (IP) assets, combined with RISEs patent pending formulation, CT will produce a product line of sexual health and wellness products under license for RISE, to be sold in California. The product line will be developed at CTs San Francisco lab and manufacturing headquarters and will be available in California retail channels in April 2018. Following the initial rollout, RISE plans to expand product sales to other U.S. states, as well as European markets. Validated science will be at the core of our product development, said Anton Mattadeen, CEO of RISE. Constance Therapeutics is a leader in creating cannabis-based extracts for use by physicians and patients. Their highly-controlled, patented extraction and formulation processes make them the ideal partner for RISE, as we are committed to evolving our intellectual property into tested and evaluated consumer products. This relationship with CT not only adds a strong foundation to support our entry into the California market, it also aligns us with one of the most trusted voices in the space. The value that Constance Finley brings to our partnership substantially advances our market position. This partnership strengthens both companies at a critical juncture in the industry, said Constance Finley, CEO and founder of Constance Therapeutics. My company has led the industry in evidence-based medicinal cannabis products for a decade now, and with the rapid expansion occurring in the California market, we recognize the need for strategic partners that support one another while allowing each company to focus even more on its core competencies. CTs new R&D and manufacturing lab in San Francisco will enable us to produce at a much greater capacity, while RISE is developing a comprehensive retail distribution and online marketing program that will give access to more patients clamoring for our products. Im thrilled to be forging ahead with RISE as we secure a dominant position in this market.
Comment by
Donlin on Jan 30, 2018 10:28am
Down 2 cents. Again the market is "impressed" with this company's move. Bad memories of MOM still running the fortunes of this company. The big question, where they going to drop the ball with this one? May be they can get the SCOUT to determine if a person is going to be a potential heavy user of weed.
Comment by
Hammertime5 on Jan 30, 2018 12:41pm
Really? Read the press Donlin, there is a new team, let it go - let it go, you know from the movie... MOM and Scout are old news, be relevant and current - these are fairly important when investing.
Comment by
Donlin on Jan 30, 2018 3:44pm
The "new" boys on the block have been around for a while. The SCOUT remains in limbo. The jury is out on MT's weed division so time will tell. Talk to you in a year. Hope I'm wrong as I would really like to recover some of my losses with a smokin' LMT